Objective
Coronavirus disease 2019 (COVID-19) caused by infection with SARS coronavirus 2 (SARS-CoV-2) has reached pandemic proportions with more than 7 million people infected and 0.4 million people killed worldwide. Death rates are accentuated by cardiovascular comorbidities and arrhythmias leading to unexpected major cardiovascular events. Being able to identify COVID-19 patients at risk of developing cardiovascular events leading to death would allow improving surveillance and care. Currently, there is no accurate method to predict outcome of COVID-19 patients. COVIRNA is a patient-centered Innovation Action aiming to satisfy this urgent and unmet need. COVIRNA will complete and deploy a prognostic system based on cardiovascular biomarkers of COVID-19 clinical outcomes combined with digital tools and artificial intelligence analytics (i.e. prediction model). Complementary expertise of 15 EU partners from the healthcare sector, academia, association and industry will allow conducting a large retrospective study on existing cohorts of COVID-19 patients. By upscaling the already validated and patented research use only FIMICS panel of cardiac-enriched long noncoding RNA biomarkers into an in-vitro diagnostic test (COVIRNA) adapted to COVID-19 patients, the project will quickly deliver a minimally-invasive, simple yet robust and affordable prognosis tool that can be used in the context of the current COVID-19 crisis as well as in further major health issues. By tackling the cardiovascular complications in COVID-19, known to contribute significantly to mortality, the project outputs are expected to have a major impact on the pandemic outcomes. The COVIRNA test will be CE-marked and prepared for commercialization, allowing to risk stratify patients, adapt therapies and to inform drug design.
Fields of science
- medical and health sciencesclinical medicinecardiologycardiovascular diseasescardiac arrhythmia
- social sciencessociologydemographymortality
- medical and health sciencesbasic medicinemedicinal chemistry
- medical and health scienceshealth sciencespublic healthepidemiologypandemics
- medical and health scienceshealth sciencesinfectious diseasesRNA virusescoronaviruses
Keywords
Programme(s)
Call for proposal
H2020-SC1-PHE-CORONAVIRUS-2020-2
See other projects for this callSub call
H2020-SC1-PHE-CORONAVIRUS-2020-2-CNECT
Funding Scheme
IA - Innovation actionCoordinator
1445 Strassen
Luxembourg
See on map
Participants (15)
68330 Huningue
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
68330 Huningue
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
4365 ESCH-SUR-ALZETTE
See on map
SW7 2AZ LONDON
See on map
6200 MD Maastricht
See on map
1000 Bruxelles / Brussel
See on map
40225 Dusseldorf
See on map
EH8 9YL Edinburgh
See on map
71210 Ilidza Sarajevo
See on map
20097 San Donato Mi
See on map
6722 Szeged
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
04109 Leipzig
See on map
1000 Ljubljana
See on map
08041 Barcelona
See on map
3004-531 Coimbra
See on map